Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sutent
Pharma
AZ, Eisai, Pfizer, Roche meds lose out in China's latest VBP
Companies making altogether 60 off-patent drugs slashed their prices by an average 48% to win supply contracts in China's latest VBP.
Angus Liu
Jul 12, 2022 11:15am
Deciphera cracks the door open for off-label cancer drug use
Jan 25, 2022 12:02pm
Merck, Eisai snare Keytruda-Lenvima kidney cancer nod
Aug 12, 2021 10:15am
Keytruda targets Pfizer's Sutent in adjuvant kidney cancer
Jun 3, 2021 5:00pm
BMS aims to battle Merck with Opdivo-Cabometyx kidney cancer nod
Jan 25, 2021 9:40am
Merck, Eisai's Keytruda-Lenvima tops Sutent in kidney cancer
Nov 11, 2020 11:59am